



Expert


ICD-10-CM Expert for Hospitals

The complete official guidelines and code set

Codes valid from October 1, 2026
through September 30, 2027

SAMPLE

2027



Contents

How to Use ICD-10-CM Expert for Hospitals 2027	iii		
Introduction	iii	Chapter 12. Diseases of the Skin and Subcutaneous Tissue (L00–L99)	747
What's New for 2027	iii	Chapter 13. Diseases of the Musculoskeletal System and Connective Tissue (M00–M99)	769
Conversion Table	iii	Chapter 14. Diseases of Genitourinary System (N00–N99).....	857
10 Steps to Correct Coding	iii	Chapter 15. Pregnancy, Childbirth, and the Puerperium (O00–O9A)	879
Official ICD-10-CM Guidelines for Coding and Reporting	iii	Chapter 16. Certain Conditions Originating in the Perinatal Period (P00–P96)	919
Indexes	iii	Chapter 17. Congenital Malformations, Deformations, and Chromosomal Abnormalities (Q00–Q99)	933
Index to Diseases and Injuries	iii	Chapter 18. Symptoms, Signs, and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified (R00–R99)	955
Neoplasm Table	iii	Chapter 19. Injury, Poisoning, and Certain Other Consequences of External Causes (S00–T88)	977
Table of Drugs and Chemicals	iii	Chapter 20. External Causes of Morbidity (V00–Y99)	1193
External Causes Index	iv	Chapter 21. Factors Influencing Health Status and Contact with Health Services (Z00–Z99)	1259
Index Notations	iv	Chapter 22. Codes for Special Purposes (U00–U85).....	1299
Tabular List of Diseases	v		
Code and Code Descriptions	v		
Tabular Notations	v		
Official Notations	v		
Optum Notations	vi		
Icons	vi		
Color Bars	vii		
Chapter-Level Notations	viii		
Appendices	viii		
Illustrations	viii		
What's New for 2027	ix	Appendices	Appendices-1
Official Updates	ix	Appendix A: Valid 3-character ICD-10-CM Codes.....	Appendices-1
Proprietary Updates	ix	Appendix B: Pharmacology List 2027.....	Appendices-3
Conversion Table of ICD-10-CM Codes	x	Appendix C: Z Codes for Long-Term Drug Use with Associated Drugs.....	Appendices-18
10 Steps to Correct Coding	xii	Appendix D: Major Complication and Comorbidity (MCC) Code List.....	Appendices-20
ICD-10-CM Official Guidelines for Coding and Reporting	Coding Guidelines-1	Appendix E: Complication and Comorbidity (CC) Code List	Appendices-24
ICD-10-CM Index to Diseases and Injuries	1	Appendix F: Present on Admission (POA) Tutorial	Appendices-38
ICD-10-CM Neoplasm Table	339	Appendix G: Hospital Acquired Conditions.....	Appendices-41
ICD-10-CM Table of Drugs and Chemicals	358	Appendix H: Centers for Medicare & Medicaid Services Hierarchical Condition Categories (CMS-HCC)	Appendices-63
ICD-10-CM Index to External Causes.....	408		
ICD-10-CM Tabular List of Diseases and Injuries	445	Illustrations	Illustrations-1
Chapter 1. Certain Infectious and Parasitic Diseases (A00–B99), U07.1, U09.9	445	Chapter 3. Diseases of the Blood and Blood-forming Organs and Certain Disorders Involving the Immune Mechanism (D50–D89)	Illustrations-1
Chapter 2. Neoplasms (C00–D49)	471	Red Blood Cells	Illustrations-1
Chapter 3. Diseases of the Blood and Blood-forming Organs and Certain Disorders Involving the Immune Mechanism (D50–D89)	513	White Blood Cell	Illustrations-1
Chapter 4. Endocrine, Nutritional, and Metabolic Diseases (E00–E89)	527	Platelet	Illustrations-2
Chapter 5. Mental, Behavioral and Neurodevelopmental Disorders (F01–F99)	551	Coagulation	Illustrations-2
Chapter 6. Diseases of the Nervous System (G00–G99)	583	Spleen Anatomical Location and External Structures	Illustrations-3
Chapter 7. Diseases of the Eye and Adnexa (H00–H59)	607	Spleen Interior Structures	Illustrations-3
Chapter 8. Diseases of the Ear and Mastoid Process (H60–H95)	645	Chapter 4. Endocrine, Nutritional, and Metabolic Diseases (E00–E89)	Illustrations-4
Chapter 9. Diseases of the Circulatory System (I00–I99)	657	Endocrine System	Illustrations-4
Chapter 10. Diseases of the Respiratory System (J00–J99), U07.0	703	Thyroid	Illustrations-5
Chapter 11. Diseases of the Digestive System (K00–K95)	721	Thyroid and Parathyroid Glands	Illustrations-5
		Pancreas	Illustrations-6
		Anatomy of the Adrenal Gland	Illustrations-6
		Structure of an Ovary	Illustrations-7
		Testis and Associated Structures	Illustrations-7
		Thymus	Illustrations-8

Chapter 6. Diseases of the Nervous System (G00–G99) .. Illustrations–9	Chapter 11. Diseases of the Digestive System (K00–K95) .. Illustrations–29
Brain Illustrations–9	Digestive System Illustrations–29
Cranial Nerves Illustrations–9	Omentum and Mesentery Illustrations–30
Peripheral Nervous System Illustrations–10	Peritoneum and Retroperitoneum Illustrations–30
Spinal Cord and Spinal Nerves Illustrations–11	
Nerve Cell Illustrations–12	
Trigeminal and Facial Nerve	
Branches Illustrations–12	
Chapter 7. Diseases of the Eye and Adnexa (H00–H59) .. Illustrations–13	Chapter 12. Diseases of the Skin and Subcutaneous Tissue (L00–L99) .. Illustrations–31
Eye Illustrations–13	Nail Anatomy Illustrations–31
Posterior Pole of Globe/Flow of	Skin and Subcutaneous Tissue Illustrations–31
Aqueous Humor Illustrations–13	
Lacrimal System Illustrations–14	
Eye Musculature Illustrations–14	
Eyelid Structures Illustrations–14	
Chapter 8. Diseases of the Ear and Mastoid Process (H60–H95) .. Illustrations–15	Chapter 13. Diseases of the Musculoskeletal System and Connective Tissue (M00–M99) .. Illustrations–32
Ear Anatomy Illustrations–15	Bones and Joints Illustrations–32
Chapter 9. Diseases of the Circulatory System (I00–I99) .. Illustrations–16	Shoulder Anterior View Illustrations–33
Anatomy of the Heart Illustrations–16	Shoulder Posterior View Illustrations–33
Heart Cross Section Illustrations–16	Elbow Anterior View Illustrations–33
Heart Valves Illustrations–17	Elbow Posterior View Illustrations–33
Heart Conduction System Illustrations–17	Hand Illustrations–33
Coronary Arteries Illustrations–18	Hip Anterior View Illustrations–34
Arteries Illustrations–19	Hip Posterior View Illustrations–34
Veins Illustrations–20	Knee Anterior View Illustrations–34
Internal Carotid and Vertebral Arteries and Branches Illustrations–21	Knee Posterior View Illustrations–34
External Carotid Artery and Branches Illustrations–21	Foot Illustrations–34
Branches of Abdominal Aorta Illustrations–22	Muscles Illustrations–35
Portal Venous Circulation Illustrations–22	
Lymphatic System Illustrations–23	
Axillary Lymph Nodes Illustrations–24	
Lymphatic System of Head and Neck Illustrations–24	
Lymphatic Capillaries Illustrations–25	
Lymphatic Drainage Illustrations–25	
Chapter 10. Diseases of the Respiratory System (J00–J99), U07.0 .. Illustrations–26	Chapter 14. Diseases of Genitourinary System (N00–N99) .. Illustrations–36
Respiratory System Illustrations–26	Urinary System Illustrations–36
Upper Respiratory System Illustrations–27	Male Genitourinary System Illustrations–37
Lower Respiratory System Illustrations–27	Female Internal Genitalia Illustrations–37
Paranasal Sinuses Illustrations–27	Female Genitourinary Tract Lateral View Illustrations–37
Lung Segments Illustrations–28	
Alveoli Illustrations–28	
	Chapter 15. Pregnancy, Childbirth, and the Puerperium (O00–O9A) .. Illustrations–38
	Term Pregnancy – Single Gestation Illustrations–38
	Twin Gestation–Dichorionic–Diamniotic (Dl-Dl) Illustrations–38
	Twin Gestation–Monochorionic–Diamniotic (MO-Dl) Illustrations–39
	Twin Gestation–Monochorionic–Monoamniotic (MO-MO) Illustrations–39
	Chapter 19. Injury, Poisoning, and Certain Other Consequences of External Causes (S00–T88) .. Illustrations–40
	Types of Fractures Illustrations–40
	Salter-Harris Fracture Types Illustrations–40

A Adult Age: 15-124

These diagnoses are intended for patients between the age of 15 and 124 years.

R54 Age-related physical debility

Frailty
Old age
Senescence
Senile asthenia
Senile debility

EXCLUDES 1 age-related cognitive decline (R41.81)
sarcopenia (M62.84)
senile psychosis (F03.-)
senility NOS (R41.81)

A**Sex Edits**

Effective October 1, 2024, the Medicare Code Editor (MCE), a program used to detect and report errors in coding claims data, has deactivated the sex conflict edit. There is no longer a female or male edit restriction for ICD-10-CM codes.

H1 - H14 Hospital Acquired Condition (HAC)

These icons identify codes that are high-cost and/or high-volume (CC or MCC), that when assigned as a secondary diagnosis result in assignment of a case to a higher-paying MS-DRG. The condition or diagnosis represented by these codes is considered reasonably preventable through the application of evidence-based guidelines. If the condition is not present on admission (meaning it developed during the hospital admission), the case will not group to the higher-paying MS-DRG based solely upon the reporting of the HAC code. Many of these HACs are conditional and are based on reporting the specific diagnosis code(s) in combination with certain procedure codes.

A comprehensive list of all HAC codes that coincide with these icons appears in appendix G, at the back of this book.

Note: Hospital-acquired conditions do not impact MS-LTC-DRG assignment.

N15.1 Renal and perinephric abscess**MCC** **Y6****CC Condition**

This icon identifies a complication or comorbidity diagnosis that may affect DRG assignment. A complication or comorbidity diagnosis, CC condition, is defined as a significant acute disease, a significant acute manifestation of a chronic disease, an advanced or end-stage chronic disease, or a chronic disease associated with systemic physiological decompensation and debility that have consistently greater impact on hospital resources.

A comprehensive list of ICD-10-CM codes considered a CC appears in appendix E, at the back of this book.

G90.59 Complex regional pain syndrome I of other specified site**CC****MCC Condition**

This icon identifies a major complication or comorbidity diagnosis that may affect DRG assignment. An MCC condition meets the same criteria as a CC condition but is associated with a higher acuity level and hospital resource consumption is expected to be higher than that for a CC condition. There are fewer conditions that meet the criteria as an MCC than those for a CC condition.

A comprehensive list of ICD-10-CM codes considered an MCC appears in appendix D, at the back of this book.

J04.11 Acute tracheitis with obstruction**MCC**

Note: The assignment of an MS-DRG or MS-LTC-DRG often depends on the presence or absence of a secondary diagnosis code that is designated as an MCC or CC. However, in some instances the MCC

or CC designation for that secondary diagnosis code is negated due to its relationship with the principal diagnosis; this is referred to as CC exclusion. The ICD-10 MS-DRG Definitions Manual included with the IPPS final rule provides a list of all principal diagnosis codes that would render ineffective the MCC/CC designation for a particular ICD-10-CM code when used as a secondary diagnosis. Optum has provided this CC exclusion list in an easily searchable data file, which can be accessed at the following:

<https://www.optumcoding.com/ProductUpdates/>
Title: "2025 ICD-10-CM for Hospitals CC Excludes Data File"
Password: HOSPITAL25

UNS Unspecified Site

This icon identifies codes that are considered an MCC or CC but lack specificity in regard to their anatomical location. The medical record documentation should be reviewed carefully, to ensure that no other code within the same category or subcategory can be assigned for greater specificity.

G81.00 Flaccid hemiplegia affecting unspecified side**CC** **UNS** **HCC****UPD Unacceptable Principal Diagnosis**

This icon identifies codes that should not be assigned as principal diagnosis for *inpatient* admissions. Codes with an unacceptable principal diagnosis edit are considered supplementary — describing circumstances that influence an individual's health status or an additional code — identifying conditions that are not specific manifestations but may be due to an underlying cause.

T48.5X5 Adverse effect of other anti-common-cold drugs**UPD** **PE****HIV HIV-related Condition**

This icon identifies codes that are considered a major HIV-related diagnosis. When the condition is coded in combination with a diagnosis of human immunodeficiency virus (HIV), code B20, the case will move from MS-DRG/MS-LTC-DRG 977 to MS-DRGs/MS-LTC-DRGs 974-976.

G96.9 Disorder of central nervous system, unspecified**HIV****PE Present on Admission Exempt**

This icon identifies codes that do not require a present on admission (POA) indicator. These codes are considered exempt because they do not represent a current disease or injury or describe conditions that are always present on admission

B90.1 Sequelae of genitourinary tuberculosis**PE****HCC CMS-HCC Condition**

This icon identifies codes that are included in the CMS-HCC risk-adjustment model.

P29.0 Neonatal cardiac failure**HCC**
Code also associated underlying condition**Color Bars****Manifestation Code**

Codes defined as manifestation codes appear in italic type, with a blue color bar over the code description. A manifestation cannot be reported as a first-listed code; it is sequenced as a secondary diagnosis with the underlying disease code listed first.

G32.89 Other specified degenerative disorders of nervous system in diseases classified elsewhere

Degenerative encephalopathy in diseases classified elsewhere

ICD-10-CM Index to Diseases and Injuries

A

Aarskog's syndrome Q87.19
Abandonment — see Maltreatment
Abasia (-astasia) (hysterical) F44.4
Abderhalden-Kaufmann-Lignac syndrome (cystinosis) E72.04
Abdomen, abdominal — see also condition
 acute R10.0
 angina K55.1
 muscle deficiency syndrome Q79.4
Abdominalgia — see Pain, abdominal
Abduction contracture, hip or other joint — see Contracture, joint
Aberrant (congenital) — see also Malposition, congenital
 adrenal gland Q89.1
 artery (peripheral) Q27.8
 basilar NEC Q28.1
 cerebral Q28.3
 coronary Q24.5
 digestive system Q27.8
 eye Q15.8
 lower limb Q27.8
 precerebral Q28.1
 pulmonary Q25.79
 renal Q27.2
 retina Q14.1
 specified site NEC Q27.8
 subclavian Q27.8
 upper limb Q27.8
 vertebral Q28.1
 breast Q83.8
 endocrine gland NEC Q89.2
 hepatic duct Q44.5
 pancreas Q45.3
 parathyroid gland Q89.2
 pituitary gland Q89.2
 sebaceous glands, mucous membrane, mouth, congenital Q38.6
 spleen Q89.09
 subclavian artery Q27.8
 thymus (gland) Q89.2
 thyroid gland Q89.2
 vein (peripheral) NEC Q27.8
 cerebral Q28.3
 digestive system Q27.8
 lower limb Q27.8
 precerebral Q28.1
 specified site NEC Q27.8
 upper limb Q27.8
Aberration
 distastial — see Disturbance, visual
 mental F99
Abetalipoproteinemia E78.6
Abiotrophy R68.89
Ablatio, ablation
 retinae — see Detachment, retina
Ablepharia, ablepharon Q10.3
Abnormal, abnormality, abnormalities — see also
 Anomaly
 acid-base balance (mixed) E87.4
 albumin R77.0
 alphafetoprotein R77.2
 alveolar ridge K08.9
 anatomical relationship Q89.9
 apertures, congenital, diaphragm Q79.1
 atrial septal, specified NEC Q21.19
 auditory perception H93.29-
 diploacus — see Diploacus
 hyperacusis — see Hyperacusis
 recruitment — see Recruitment, auditory
 threshold shift — see Shift, auditory threshold
 autosomes Q99.9
 fragile site Q95.5
 basal metabolic rate R94.8
 biosynthesis, testicular androgen E29.1
 bleeding time R79.1
 blood amino-acid level R79.83
 blood level (of)
 cobalt R79.0
 copper R79.0
 iron R79.0

Abnormal, abnormality, abnormalities — continued
 blood level — continued
 lithium R78.89
 magnesium R79.0
 mineral NEC R79.0
 zinc R79.0
 blood pressure
 elevated R03.0
 low reading (nonspecific) R03.1
 blood sugar R73.09
 blood-gas level R79.81
 bowel sounds R19.15
 absent R19.11
 hyperactive R19.12
 brain scan R94.02
 breathing R06.9
 caloric test R94.138
 cerebrospinal fluid R83.9
 cytology R83.6
 drug level R83.2
 enzyme level R83.0
 hormones R83.1
 immunology R83.4
 microbiology R83.5
 nonmedicinal level R83.3
 specified type NEC R83.8
 chemistry, blood R79.9
 C-reactive protein R79.82
 drugs — see Findings, abnormal, in blood
 gas level R79.81
 minerals R79.0
 pancytopenia D61.818
 PTT R79.1
 specified NEC R79.89
 toxins — see Findings, abnormal, in blood
 chest sounds (friction) (rales) R09.89
 chromosome, chromosomal Q99.9
 with more than three X chromosomes, female Q97.1
 analysis result R89.8
 bronchial washings R84.8
 cerebrospinal fluid R83.8
 cervix uteri NEC R78.89
 nasal secretions R84.8
 nipple discharge R89.8
 peritoneal fluid R85.89
 pleural fluid R84.8
 prostatic secretions R86.8
 saliva R85.89
 seminal fluid R86.8
 sputum R84.8
 synovial fluid R89.8
 throat scrapings R84.8
 vagina R87.89
 vulva R87.89
 wound secretions R89.8
 dicentriate replacement Q93.2
 ring replacement Q93.2
 sex Q99.8
 female phenotype Q97.9
 specified NEC Q97.8
 male phenotype Q98.9
 specified NEC Q98.8
 structural male Q98.6
 specified NEC Q99.8
 clinical findings NEC R68.89
 coagulation D68.9
 newborn, transient P61.6
 profile R79.1
 time R79.1
 communication — see Fistula
 conjunctiva, vascular H11.41-
 coronary artery Q24.5
 cortisol-binding globulin E27.8
 course, eustachian tube Q17.8
 creatinine clearance R94.4
 cytology
 anus R85.619
 atypical squamous cells cannot exclude high grade squamous intraepithelial lesion (ASC-H) R85.611
 atypical squamous cells of undetermined significance (ASC-US) R85.610
 cytologic evidence of malignancy R85.614
Abnormal, abnormality, abnormalities — continued
 cytology — continued
 anus — continued
 high grade squamous intraepithelial lesion (HSIL) R85.613
 human papillomavirus (HPV) DNA test
 high risk positive R85.81
 low risk positive R85.82
 inadequate smear R85.615
 low grade squamous intraepithelial lesion (LSIL) R85.612
 satisfactory anal smear but lacking transformation zone R85.616
 specified NEC R85.618
 unsatisfactory smear R85.615
 female genital organs — see Abnormal, Papanicolaou (smear)
 dark adaptation curve H53.61
 dentofacial NEC — see Anomaly, dentofacial development, developmental Q89.9
 central nervous system Q07.9
 diagnostic imaging
 abdomen, abdominal region NEC R93.5
 biliary tract R93.2
 bladder R93.41
 breast R92.8
 central nervous system NEC R90.89
 cerebrovascular NEC R90.89
 coronary circulation R93.1
 digestive tract NEC R93.3
 gastrointestinal (tract) R93.3
 genitourinary organs R93.89
 head R93.0
 heart R93.1
 intrathoracic organ NEC R93.89
 kidney R93.42-
 limbs R93.6
 liver R93.2
 lung (field) R91.8
 musculoskeletal system NEC R93.7
 renal pelvis R93.41
 retroperitoneum R93.5
 site specified NEC R93.89
 skin and subcutaneous tissue R93.89
 skull R93.0
 testis R93.81-
 ureter R93.41
 urinary organs specified NEC R93.49
 direction, teeth, fully erupted M26.30
 ear ossicles, acquired NEC H74.39-
 ankylosis — see Ankylosis, ear ossicles
 discontinuity — see Discontinuity, ossicles, ear
 partial loss — see Loss, ossicles, ear (partial)
 Ebstein Q22.5
 echocardiogram R93.1
 echoencephalogram R90.81
 echogram — see Abnormal, diagnostic imaging
 electrocardiogram [ECG] [EKG] R94.31
 electroencephalogram [EEG] R94.01
 electrolyte — see Imbalance, electrolyte
 electromyogram [EMG] R94.131
 electro-oculogram [EOG] R94.110
 electrophysiological intracardiac studies R94.39
 electroretinogram [ERG] R94.111
 erythrocytes
 congenital, with perinatal jaundice D58.9
 feces (color) (contents) (mucus) R19.5
 finding — see Findings, abnormal, without diagnosis fluid
 amniotic — see Abnormal, specimen, specified
 cerebrospinal — see Abnormal, cerebrospinal fluid
 peritoneal — see Abnormal, specimen, digestive organs
 pleural — see Abnormal, specimen, respiratory organs
 synovial — see Abnormal, specimen, specified
 thorax (bronchial washings) (pleural fluid) — see Abnormal, specimen, respiratory organs
 vaginal — see Abnormal, specimen, female genital organs
 form
 teeth K00.2
 uterus — see Anomaly, uterus

	Malignant Primary	Malignant Secondary	Ca in situ	Benign	Uncertain Behavior	Unspecified Behavior		Malignant Primary	Malignant Secondary	Ca in situ	Benign	Uncertain Behavior	Unspecified Behavior
Neoplasm, neoplastic — continued							Neoplasm, neoplastic — continued						
brain — continued							bronchus — continued						
basal ganglia	C71.0	C79.31	—	D33.0	D43.0	D49.6	main	C34.0-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1
cerebellopontine angle	C71.6	C79.31	—	D33.1	D43.1	D49.6	middle lobe of lung	C34.2	C78.0-✓	D02.21	D14.31	D38.1	D49.1
cerebellum NOS	C71.6	C79.31	—	D33.1	D43.1	D49.6	overlapping lesion	C34.8-✓	—	—	—	—	—
cerebrum	C71.0	C79.31	—	D33.0	D43.0	D49.6	upper lobe of lung	C34.1-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1
choroid plexus	C71.7	C79.31	—	D33.1	D43.1	D49.6	brow	C44.309	C79.2	D04.39	D23.39	D48.5	D49.2
corpus callosum	C71.8	C79.31	—	D33.2	D43.2	D49.6	basal cell carcinoma	C44.319	—	—	—	—	—
corpus striatum	C71.0	C79.31	—	D33.0	D43.0	D49.6	specified type NEC	C44.399	—	—	—	—	—
cortex (cerebral)	C71.0	C79.31	—	D33.0	D43.0	D49.6	squamous cell carcinoma	C44.329	—	—	—	—	—
frontal lobe	C71.1	C79.31	—	D33.0	D43.0	D49.6	buccal (cavity)	C06.9	C79.89	D00.00	D10.39	D37.09	D49.0
globus pallidus	C71.0	C79.31	—	D33.0	D43.0	D49.6	commissure	C06.0	C79.89	D00.02	D10.39	D37.09	D49.0
hippocampus	C71.2	C79.31	—	D33.0	D43.0	D49.6	groove (lower) (upper)	C06.1	C79.89	D00.02	D10.39	D37.09	D49.0
hypothalamus	C71.0	C79.31	—	D33.0	D43.0	D49.6	mucosa	C06.0	C79.89	D00.02	D10.39	D37.09	D49.0
internal capsule	C71.0	C79.31	—	D33.0	D43.0	D49.6	sulcus (lower) (upper)	C06.1	C79.89	D00.02	D10.39	D37.09	D49.0
medulla							bulbourethral gland	C68.0	C79.19	D09.19	D30.4	D41.3	D49.59
oblongata	C71.7	C79.31	—	D33.1	D43.1	D49.6	bursa — see Neoplasm, connective tissue						
meninges	C70.0	C79.32	—	D32.0	D42.0	D49.7	buttock NEC	C76.3	C79.89	D04.5	D36.7	D48.7	D49.89
midbrain	C71.7	C79.31	—	D33.1	D43.1	D49.6	calf	C76.5-✓	C79.89	D04.7-✓	D36.7	D48.7	D49.89
occipital lobe	C71.4	C79.31	—	D33.0	D43.0	D49.6	calvarium	C41.0	C79.51	—	D16.4	D48.0	D49.2
overlapping lesion	C71.8	C79.31	—	—	—	—	calyx, renal canal	C65.-✓	C79.0-✓	D09.19	D30.1-✓	D41.1-✓	D49.51-✓
parietal lobe	C71.3	C79.31	—	D33.0	D43.0	D49.6	anal	C21.1	C78.5	D01.3	D12.9	D37.8	D49.0
peduncle	C71.7	C79.31	—	D33.1	D43.1	D49.6	auditory (external) — see also Neoplasm, skin, ear						
pons	C71.7	C79.31	—	D33.1	D43.1	D49.6	auricular (external) — see also Neoplasm, skin, ear	C44.20-✓	C79.2	D04.2-✓	D23.2-✓	D48.5	D49.2
stem	C71.7	C79.31	—	D33.1	D43.1	D49.6	canalicular, biliary (biliferi) (intrahepatic)						
tapetum	C71.8	C79.31	—	D33.2	D43.2	D49.6	canthus (eye) (inner) (outer)	C22.1	C78.7	D01.5	D13.4	D37.6	D49.0
temporal lobe	C71.2	C79.31	—	D33.0	D43.0	D49.6	basal cell carcinoma						
thalamus	C71.0	C79.31	—	D33.0	D43.0	D49.6	sebaceous cell carcinoma	C44.11-✓	—	—	—	—	—
uncus	C71.2	C79.31	—	D33.0	D43.0	D49.6	specified type NEC	C44.13-✓	—	—	—	—	—
ventricle (floor) fourth	C71.5	C79.31	—	D33.0	D43.0	D49.6	squamous cell carcinoma	C44.19-✓	—	—	—	—	—
branchial (cleft) (cyst) (vestiges)	C71.7	C79.31	—	D33.1	D43.1	D49.6	capillary — see Neoplasm, connective tissue						
breast (connective tissue) (glandular tissue) (soft parts)	C10.4	C79.89	D00.08	D10.5	D37.05	D49.0	caput coli	C18.0	C78.5	D01.0	D12.0	D37.4	D49.0
areola	C50.9-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	carcinoid — see Tumor, carcinoid						
axillary tail	C50.0-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	cardia (gastric)	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
central portion	C50.6-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	cardiac orifice (stomach)	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
inner	C50.1-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	cardio-esophageal junction	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
lower	C50.8-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	cardio-esophagus	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
lower-inner quadrant	C50.3-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	carina (bronchus)	C34.0-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1
lower-outer quadrant	C50.5-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	carotid (artery) body	C49.0	C79.89	—	D21.0	D48.1-✓	D49.2
mastectomy site (skin) — see also Neoplasm, breast, skin							carpus (any bone)	C75.4	C79.89	—	D35.5	D44.6	D49.7
specified as breast tissue	C44.501	C79.2	—	—	—	—	cartilage (articular) (joint) NEC — see also Neoplasm, bone	C40.1-✓	C79.51	—	D16.1-✓	—	—
midline	C50.8-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	arytenoid	C41.9	C79.51	—	D16.9	D48.0	D49.2
nipple	C50.0-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	auricular	C32.3	C78.39	D02.0	D14.1	D38.0	D49.1
outer overlapping lesion	C50.8-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	bronchi	C34.0-✓	C78.39	—	D21.0	D48.1-✓	D49.2
skin	C50.8-✓	—	—	—	—	—	costal	C41.3	C79.51	—	D16.7	D48.0	D49.2
basal cell carcinoma	C44.501	C79.2	D04.5	D23.5	D48.5	—	cricoid	C32.3	C78.39	D02.0	D14.1	D38.0	D49.1
specified type NEC	C44.511	—	—	—	—	—	cuneiform	C32.3	C78.39	D02.0	D14.1	D38.0	D49.1
squamous cell carcinoma	C44.521	—	—	—	—	—	ear (external)	C49.0	C79.89	—	D21.0	D48.1-✓	D49.2
tail (axillary)	C50.6-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	ensiform	C41.3	C79.51	—	D16.7	D48.0	D49.2
upper	C50.8-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	epiglottis	C32.1	C78.39	D02.0	D14.1	D38.0	D49.1
upper-inner quadrant	C50.2-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3							
upper-outer quadrant	C50.4-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3							
broad ligament	C57.1-✓	C79.82	D07.39	D28.2	D39.8	D49.59							
bronchiogenic, bronchogenic (lung)	C34.9-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							
bronchiale	C34.9-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							
bronchus	C34.9-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							
carina	C34.0-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							
lower lobe of lung	C34.3-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							

Substance	Poisoning, Accidental (unintentional)	Poisoning, Intentional Self-harm	Poisoning, Assault	Poisoning, Undetermined	Adverse Effect	Under-dosing	Substance	Poisoning, Accidental (unintentional)	Poisoning, Intentional Self-harm	Poisoning, Assault	Poisoning, Undetermined	Adverse Effect	Under-dosing
Androstalone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6	Anthiolimine	T37.4X1	T37.4X2	T37.4X3	T37.4X4	T37.4X5	T37.4X6
Androstanolone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6	Anthralin	T49.4X1	T49.4X2	T49.4X3	T49.4X4	T49.4X5	T49.4X6
Androsterone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6	Anthramycin	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
Anemone pulsatilla	T62.2X1	T62.2X2	T62.2X3	T62.2X4	—	—	Antidiuretic NEC	T44.8X1	T44.8X2	T44.8X3	T44.8X4	T44.8X5	T44.8X6
Anesthesia							Antiallergic NEC	T45.0X1	T45.0X2	T45.0X3	T45.0X4	T45.0X5	T45.0X6
caudal	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antiandrogen NEC	T38.6X1	T38.6X2	T38.6X3	T38.6X4	T38.6X5	T38.6X6
endotracheal	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6	Anti-anemic (drug) (preparation)	T45.8X1	T45.8X2	T45.8X3	T45.8X4	T45.8X5	T45.8X6
epidural	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antianxiety drug NEC	T43.501	T43.502	T43.503	T43.504	T43.505	T43.506
inhalation	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6	Antiaris toxicaria	T65.891	T65.892	T65.893	T65.894	—	—
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antiarteriosclerotic drug	T46.6X1	T46.6X2	T46.6X3	T46.6X4	T46.6X5	T46.6X6
mucosal	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antiasthmatic drug NEC	T48.6X1	T48.6X2	T48.6X3	T48.6X4	T48.6X5	T48.6X6
muscle relaxation	T48.1X1	T48.1X2	T48.1X3	T48.1X4	T48.1X5	T48.1X6	Antibiotic Otic Suspension (Solution)*	T49.6X1	T49.6X2	T49.6X3	T49.6X4	T49.6X5	T49.6X6
nerve blocking	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
plexus blocking	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
potentiated	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
rectal	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
regional	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
surface	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
Anesthetic NEC — see also Anesthesia	T41.41	T41.42	T41.43	T41.44	T41.45	T41.46							
with muscle relaxant	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
gaseous NEC	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6							
general NEC	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
halogenated hydrocarbon derivatives NEC	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6							
infiltration NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
intravenous NEC	T41.1X1	T41.1X2	T41.1X3	T41.1X4	T41.1X5	T41.1X6							
local NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
rectal	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
regional NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
spinal NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
thiobarbiturate	T41.1X1	T41.1X2	T41.1X3	T41.1X4	T41.1X5	T41.1X6							
topical	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
Aneurine	T45.2X1	T45.2X2	T45.2X3	T45.2X4	T45.2X5	T45.2X6							
Angeliq*	T38.5X1	T38.5X2	T38.5X3	T38.5X4	T38.5X5	T38.5X6							
Angio-Conray	T50.8X1	T50.8X2	T50.8X3	T50.8X4	T50.8X5	T50.8X6							
Angiotensin	T44.5X1	T44.5X2	T44.5X3	T44.5X4	T44.5X5	T44.5X6							
Angiotensinamide	T44.991	T44.992	T44.993	T44.994	T44.995	T44.996							
Anhydrohydroxy-progesterone	T38.5X1	T38.5X2	T38.5X3	T38.5X4	T38.5X5	T38.5X6							
Anhydron	T50.2X1	T50.2X2	T50.2X3	T50.2X4	T50.2X5	T50.2X6							
Anileridine	T40.491	T40.492	T40.493	T40.494	T40.495	T40.496							
Aniline (dye) (liquid)	T65.3X1	T65.3X2	T65.3X3	T65.3X4	—	—							
analgesic derivatives, therapeutic NEC	T39.1X1	T39.1X2	T39.1X3	T39.1X4	T39.1X5	T39.1X6							
vapor	T65.3X1	T65.3X2	T65.3X3	T65.3X4	—	—							
Anisocorpine	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6							
Anise oil	T47.5X1	T47.5X2	T47.5X3	T47.5X4	T47.5X5	T47.5X6							
Anisidine	T65.3X1	T65.3X2	T65.3X3	T65.3X4	—	—							
Anisindione	T45.511	T45.512	T45.513	T45.514	T45.515	T45.516							
Anisotropine methyl-bromide	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6							
Anistreplase	T45.611	T45.612	T45.613	T45.614	T45.615	T45.616							
Anorexiant (central)	T50.5X1	T50.5X2	T50.5X3	T50.5X4	T50.5X5	T50.5X6							
Anorexic agents	T50.5X1	T50.5X2	T50.5X3	T50.5X4	T50.5X5	T50.5X6							
Ansaid*	T39.311	T39.312	T39.313	T39.314	T39.315	T39.316							
Ansamycin	T36.6X1	T36.6X2	T36.6X3	T36.6X4	T36.6X5	T36.6X6							
Ant (bite) (sting)	T63.421	T63.422	T63.423	T63.424	—	—							
Antabuse	T50.6X1	T50.6X2	T50.6X3	T50.6X4	T50.6X5	T50.6X6							
Antacid NEC	T47.1X1	T47.1X2	T47.1X3	T47.1X4	T47.1X5	T47.1X6							
Antagonist													
Aldosterone	T50.0X1	T50.0X2	T50.0X3	T50.0X4	T50.0X5	T50.0X6							
alpha-adrenoreceptor	T44.6X1	T44.6X2	T44.6X3	T44.6X4	T44.6X5	T44.6X6							
anticoagulant	T45.7X1	T45.7X2	T45.7X3	T45.7X4	T45.7X5	T45.7X6							
beta-adrenoreceptor	T44.7X1	T44.7X2	T44.7X3	T44.7X4	T44.7X5	T44.7X6							
extrapyramidal NEC	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6							
folic acid	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6							
H2 receptor	T47.0X1	T47.0X2	T47.0X3	T47.0X4	T47.0X5	T47.0X6							
heavy metal	T45.8X1	T45.8X2	T45.8X3	T45.8X4	T45.8X5	T45.8X6							
narcotic analgesic	T50.7X1	T50.7X2	T50.7X3	T50.7X4	T50.7X5	T50.7X6							
opiate	T50.7X1	T50.7X2	T50.7X3	T50.7X4	T50.7X5	T50.7X6							
pyrimidine	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6							
serotonin	T46.5X1	T46.5X2	T46.5X3	T46.5X4	T46.5X5	T46.5X6							
Antazolin (e)	T45.0X1	T45.0X2	T45.0X3	T45.0X4	T45.0X5	T45.0X6							
Anterior pituitary hormone NEC	T38.811	T38.812	T38.813	T38.814	T38.815	T38.816							
Anthelmintic NEC	T37.4X1	T37.4X2	T37.4X3	T37.4X4	T37.4X5	T37.4X6							

Chapter 2. Neoplasms (C00–D49)

Chapter-specific Guidelines with Coding Examples

The chapter-specific guidelines from the ICD-10-CM Official Guidelines for Coding and Reporting have been provided below. Along with these guidelines are coding examples, contained in the shaded boxes, that have been developed to help illustrate the coding and/or sequencing guidance found in these guidelines.

General guidelines

Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms, such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary (metastatic) sites should also be determined.

Primary malignant neoplasms overlapping site boundaries

A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned.

A 73-year-old white female with a large rapidly growing malignant tumor in the left breast extending from the upper outer quadrant into the axillary tail

C50.812 Malignant neoplasm of overlapping sites of left female breast

Explanation: Because this is a single large tumor that overlaps two contiguous sites, a single code for overlapping sites is assigned.

A 52-year old white female with two distinct lesions of the right breast, one (0.5 cm) in the upper outer quadrant and a second (1.5 cm) in the lower outer quadrant; path report indicates both lesions are malignant

C50.411 Malignant neoplasm of upper-outer quadrant of right female breast

C50.511 Malignant neoplasm of lower-outer quadrant of right female breast

Explanation: This patient has two distinct malignant lesions of right breast in adjacent quadrants. Because the lesions are not contiguous, two codes are reported.

Malignant neoplasm of ectopic tissue

Malignant neoplasms of ectopic tissue are to be coded to the site of origin mentioned, e.g., ectopic pancreatic malignant neoplasms involving the stomach are coded to malignant neoplasm of pancreas, unspecified (C25.9).

The neoplasm table in the Alphabetic Index should be referenced first. However, if the histological term is documented, that term should be referenced first, rather than going immediately to the Neoplasm Table, in order to determine which column in the Neoplasm Table is appropriate. For example, if the documentation indicates "adenoma," refer to the term in the Alphabetic Index to review the entries under this term and the instructional note to "see also neoplasm, by site, benign." The table provides the proper code based on the type of neoplasm and the site. It is important to select the proper column in the table that corresponds to the type of neoplasm. The Tabular List should then be referenced to verify that the correct code has been selected from the table and that a more specific site code does not exist.

See Section I.C.21. Factors influencing health status and contact with health services, Status, for information regarding Z15.0, codes for genetic susceptibility to cancer.

a. Admission/Encounter for treatment of primary site

If the malignancy is chiefly responsible for occasioning the patient admission/encounter and treatment is directed at the primary site, designate the primary malignancy as the principal/first-listed diagnosis.

The only exception to this guideline is if the administration of chemotherapy, immunotherapy or external beam radiation therapy is chiefly responsible for occasioning the admission/encounter. In that case, assign the appropriate Z51. -- code as the first-listed or principal diagnosis, and the underlying diagnosis or problem for which the service is being performed as a secondary diagnosis.

b. Admission/Encounter for treatment of secondary site

When a patient is admitted because of a primary neoplasm with metastasis and treatment is directed toward the secondary site only, the secondary

neoplasm is designated as the principal diagnosis even though the primary malignancy is still present.

Patient with primary prostate cancer with metastasis to lungs admitted for wedge resection of mass in right lung

C78.01 Secondary malignant neoplasm of right lung

C61 Malignant neoplasm of prostate

Explanation: Since the admission is for treatment of the lung metastasis, the secondary lung metastasis is sequenced before the primary prostate cancer.

c. Coding and sequencing of complications

Coding and sequencing of complications associated with the malignancies or with the therapy thereof are subject to the following guidelines:

1) Anemia associated with malignancy

When admission/encounter is for management of an anemia associated with the malignancy, and the treatment is only for anemia, the appropriate code for the malignancy is sequenced as the principal or first-listed diagnosis followed by the appropriate code for the anemia (such as code D63.0, Anemia in neoplastic disease).

Patient is admitted for treatment of anemia in advanced colon cancer

C18.9 Malignant neoplasm of colon, unspecified

D63.0 Anemia in neoplastic disease

Explanation: Even though the admission was solely to treat the anemia, this guideline indicates that the code for the malignancy is sequenced first.

2) Anemia associated with chemotherapy, immunotherapy and radiation therapy

When the admission/encounter is for management of an anemia associated with an adverse effect of the administration of chemotherapy or immunotherapy and the only treatment is for the anemia, the anemia code is sequenced first followed by the appropriate codes for the neoplasm and the adverse effect (T45.1X5, Adverse effect of antineoplastic and immunosuppressive drugs).

A 56-year-old Hispanic male with grade II follicular lymphoma involving multiple lymph node sites referred for blood transfusion to treat anemia due to chemotherapy

D64.81 Anemia due to antineoplastic chemotherapy

C82.18 Follicular lymphoma grade II, lymph nodes of multiple sites

T45.1X5A Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter

Explanation: The code for the anemia is sequenced first followed by the code for the malignant neoplasm and lastly the code for the adverse effect.

When the admission/encounter is for management of an anemia associated with an adverse effect of radiotherapy, the anemia code should be sequenced first, followed by the appropriate neoplasm code and code Y84.2, Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure.

A 55-year-old male with a large malignant rectal tumor has been receiving external radiation therapy to shrink the tumor prior to planned surgery. He is admitted today for a blood transfusion to treat anemia related to radiation therapy.

D64.89 Other specified anemias

C20 Malignant neoplasm of rectum

Y84.2 Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

Explanation: The code for the anemia is sequenced first, followed by the code for the malignancy, and lastly the code for the abnormal reaction due to radiotherapy.

I72 Other aneurysm

INCLUDES aneurysm (ciroid) (false) (ruptured)

EXCLUDES 2 acquired aneurysm (I77.0-)
aneurysm (of) aorta (I71.-)
aneurysm (of) arteriovenous NOS (Q27.3-)
carotid artery dissection (I77.71)
cerebral (nonruptured) aneurysm (I67.1)
coronary aneurysm (I25.4)
coronary artery dissection (I25.42)
dissection of artery NEC (I77.79)
dissection of precerebral artery, congenital (nonruptured) (Q28.1)
heart aneurysm (I25.3)
iliac artery dissection (I77.72)
precerebral artery, congenital (nonruptured) (Q28.1)
pulmonary artery aneurysm (I28.1)
renal artery dissection (I77.73)
retinal aneurysm (H35.0)
ruptured cerebral aneurysm (I60.7)
varicose aneurysm (I77.0)
vertebral artery dissection (I77.74)

AHA: 2016,4Q,28-29

I72.0 Aneurysm of carotid artery

Aneurysm of common carotid artery
Aneurysm of external carotid artery
Aneurysm of internal carotid artery, extracranial portion

EXCLUDES 1 aneurysm of internal carotid artery, intracranial portion (I67.1)
aneurysm of internal carotid artery NOS (I67.1)

I72.1 Aneurysm of artery of upper extremity

I72.2 Aneurysm of renal artery

I72.3 Aneurysm of iliac artery

I72.4 Aneurysm of artery of lower extremity

AHA: 2019,2Q,21

I72.5 Aneurysm of other precerebral arteries

Aneurysm of basilar artery (trunk)


EXCLUDES 2 aneurysm of carotid artery (I72.0)
aneurysm of vertebral artery (I72.6)
dissection of carotid artery (I77.71)
dissection of other precerebral arteries (I77.75)
dissection of vertebral artery (I77.74)

I72.6 Aneurysm of vertebral artery

EXCLUDES 2 dissection of vertebral artery (I77.74)

I72.8 Aneurysm of other specified arteries

I72.9 Aneurysm of unspecified site



I73 Other peripheral vascular diseases

EXCLUDES 2 chilblains (T69.1)
frostbite (T33-T34)
immersion hand or foot (T69.0-)
spasm of cerebral artery (G45.9)

AHA: 2018,4Q,87

I73.0 Raynaud's syndrome

Raynaud's disease
Raynaud's phenomenon (secondary)

DEF: Constriction of the arteries of the digits caused by cold or by nerve or arterial damage and can be prompted by stress or emotion. Blood cannot reach the skin and soft tissues and the skin turns white with blue mottling.

I73.00 Raynaud's syndrome without gangrene

I73.01 Raynaud's syndrome with gangrene

I73.1 Thromboangiitis obliterans [Buerger's disease]

DEF: Inflammatory disease of the extremity blood vessels, mainly the lower blood vessels. This disease is associated with heavy tobacco use. The arteries are more affected than veins. It occurs primarily in young men and leads to tissue ischemia and gangrene.

I73.8 Other specified peripheral vascular diseases

EXCLUDES 1 diabetic (peripheral) angiopathy (E08-E13 with .51-.52)

I73.81 Erythromelalgia

I73.89 Other specified peripheral vascular diseases

Acrocyanosis
Erythrocyanosis
Simple acroparesthesia [Schultze's type]
Vasomotor acroparesthesia [Nothnagel's type]

I73.9 Peripheral vascular disease, unspecified

Intermittent claudication
Peripheral angiopathy NOS
Spasm of artery

EXCLUDES 1 atherosclerosis of the extremities (I70.2-I70.7-)

AHA: 2018,2Q,7

I74 Arterial embolism and thrombosis

INCLUDES embolic infarction
embolic occlusion
thrombotic infarction
thrombotic occlusion

Code first:

embolism and thrombosis complicating abortion or ectopic or molar pregnancy (O00-O07, O08.2)
embolism and thrombosis complicating pregnancy, childbirth and the puerperium (O88.-)

EXCLUDES 2 atheroembolism (I75.-)
basilar embolism and thrombosis (I63.0-I63.2, I65.1)
carotid embolism and thrombosis (I63.0-I63.2, I65.2)
cerebral embolism and thrombosis (I63.3-I63.5, I66.-)
coronary embolism and thrombosis (I21-I25)
mesenteric embolism and thrombosis (K55.0-)
ophthalmic embolism and thrombosis (H34.-)
precerebral embolism and thrombosis NOS (I63.0-I63.2, I65.9)
pulmonary embolism and thrombosis (I26.-)
renal embolism and thrombosis (N28.0)
retinal embolism and thrombosis (H34.-)
septic embolism and thrombosis (I76)
vertebral embolism and thrombosis (I63.0-I63.2, I65.0)

AHA: 2023,2Q,7

I74.0 Embolism and thrombosis of abdominal aorta

I74.01 Saddle embolus of abdominal aorta MCC HCC

I74.09 Other arterial embolism and thrombosis of abdominal aorta CC HCC

Aortic bifurcation syndrome
Aortoiliac obstruction
Leriche's syndrome

I74.1 Embolism and thrombosis of other and unspecified parts of aorta

I74.10 Embolism and thrombosis of unspecified parts of aorta CC HCC

I74.11 Embolism and thrombosis of thoracic aorta CC HCC

I74.19 Embolism and thrombosis of other parts of aorta CC HCC

I74.2 Embolism and thrombosis of arteries of the upper extremities

I74.3 Embolism and thrombosis of arteries of the lower extremities CC HCC

I74.4 Embolism and thrombosis of arteries of extremities, unspecified

Peripheral arterial embolism NOS CC HCC

I74.5 Embolism and thrombosis of iliac artery

I74.8 Embolism and thrombosis of other arteries CC HCC

I74.9 Embolism and thrombosis of unspecified artery

I75 Atheroembolism

INCLUDES atherothrombotic microembolism
cholesterol embolism

I75.0 Atheroembolism of extremities

I75.01 Atheroembolism of upper extremity

I75.011 Atheroembolism of right upper extremity CC HCC

N07.5 Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis cc

Hereditary nephropathy, not elsewhere classified with membranoproliferative glomerulonephritis, types 1 and 3, or NOS

EXCLUDES 1 hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis (N07.4)
hereditary nephropathy, not elsewhere classified with C3 glomerulopathy (N07.5)

N07.6 Hereditary nephropathy, not elsewhere classified with dense deposit disease

Hereditary nephropathy, not elsewhere classified with C3 glomerulopathy with dense deposit disease
Hereditary nephropathy, not elsewhere classified with membranoproliferative glomerulonephritis, type 2

N07.7 Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis

Hereditary nephropathy, not elsewhere classified with extracapillary glomerulonephritis

N07.8 Hereditary nephropathy, not elsewhere classified with other morphologic lesions

Hereditary nephropathy, not elsewhere classified with proliferative glomerulonephritis NOS

N07.9 Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions**N07.4 Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis** cc

Hereditary nephropathy, not elsewhere classified with C3 glomerulopathy

EXCLUDES 1 hereditary nephropathy, not elsewhere classified (with C3 glomerulopathy) with dense deposit disease (N07.6)

N08 Glomerular disorders in diseases classified elsewhere

Glomerulonephritis

Nephritis

Nephropathy

Code first underlying disease, such as:

amyloidosis (E85-)
congenital syphilis (A50.5)
cryoglobulinemia (D89.1)
disseminated intravascular coagulation (D65)
gout (M1A.-, M10.-)
microscopic polyangiitis (M31.7)
multiple myeloma (C90.0-)
sepsis (A40.0-A41.9)
sickle-cell disease (D57.0-D57.8)

EXCLUDES 1 glomerulonephritis, nephritis and nephropathy (in):
antiglomerular basement membrane disease (M31.0)
diabetes (E08-E13 with .21)
gonococcal (A54.21)
Goodpasture's syndrome (M31.0)
hemolytic-uremic syndrome (D59.3-)
lupus (M32.14)
mumps (B26.83)
syphilis (A52.75)
systemic lupus erythematosus (M32.14)
Wegener's granulomatosis (M31.31)
pyelonephritis in diseases classified elsewhere (N16)
renal tubulo-interstitial disorders classified elsewhere (N16)

Renal tubulo-interstitial diseases (N10-N16)

INCLUDES pyelonephritis

EXCLUDES 1 pyeloureteritis cystica (N28.85)

N10 Acute pyelonephritis

Acute infectious interstitial nephritis
Acute pyelitis
Acute tubulo-interstitial nephritis
Hemoglobin nephrosis
Myoglobin nephrosis

Use additional code (B95-B97), to identify infectious agent

AHA: 2020,3Q,25; 2019,3Q,13

N11 Chronic tubulo-interstitial nephritis

INCLUDES chronic infectious interstitial nephritis
chronic pyelitis
chronic pyelonephritis

Use additional code (B95-B97), to identify infectious agent

N11.0 Nonobstructive reflux-associated chronic pyelonephritis

Pyelonephritis (chronic) associated with (vesicoureteral) reflux

EXCLUDES 1 vesicoureteral reflux NOS (N13.70)

N11.1 Chronic obstructive pyelonephritis cc

Pyelonephritis (chronic) associated with anomaly of pelviureteric junction
Pyelonephritis (chronic) associated with anomaly of pyeloureteric junction
Pyelonephritis (chronic) associated with crossing of vessel
Pyelonephritis (chronic) associated with kinking of ureter
Pyelonephritis (chronic) associated with obstruction of ureter
Pyelonephritis (chronic) associated with stricture of pelviureteric junction
Pyelonephritis (chronic) associated with stricture of ureter

EXCLUDES 1 calculous pyelonephritis (N20.9)

obstructive uropathy (N13.-)

N11.8 Other chronic tubulo-interstitial nephritis

Nonobstructive chronic pyelonephritis NOS

N11.9 Chronic tubulo-interstitial nephritis, unspecified cc H6

Chronic interstitial nephritis NOS

Chronic pyelitis NOS

Chronic pyelonephritis NOS

N12 Tubulo-interstitial nephritis, not specified as acute or chronic cc H6

Interstitial nephritis NOS

Pyelitis NOS

Pyelonephritis NOS

EXCLUDES 1 calculous pyelonephritis (N20.9)

N13 Obstructive and reflux uropathy

EXCLUDES 2 calculus of kidney and ureter without hydronephrosis (N20.-)
congenital obstructive defects of renal pelvis and ureter (Q62.0-Q62.3)

hydronephrosis with ureteropelvic junction obstruction (Q62.11)
obstructive pyelonephritis (N11.1)


DEF: Hydronephrosis: Distension of the kidney caused by an accumulation of urine that cannot flow out due to an obstruction that may be caused by conditions such as kidney stones or vesicoureteral reflux.

N13.0 Hydronephrosis with ureteropelvic junction obstruction cc

Hydronephrosis due to acquired occlusion of ureteropelvic junction

EXCLUDES 2 hydronephrosis with ureteropelvic junction obstruction due to calculus (N13.2)

AHA: 2016,4Q,43

Hydronephrosis/UPJ Obstruction

Q18.2 Other branchial cleft malformations	PE
Branchial cleft malformation NOS	
Cervical auricle	
Otocephaly	
Q18.3 Webbing of neck	PE
Pterygium colli	
DEF: Congenital malformation characterized by a thick, triangular skinfold that stretches from the lateral side of the neck across the shoulder. It is associated with genetic conditions such as Turner's and Noonan's syndromes.	
Q18.4 Macrostomia	PE
DEF: Rare congenital craniofacial bilateral or unilateral anomaly of the mouth due to malformed maxillary and mandibular processes. It results in an abnormally large mouth extending toward the ear.	
Q18.5 Microstomia	PE
Q18.6 Macrocheilia	PE
Hypertrophy of lip, congenital	
Q18.7 Microcheilia	PE
Q18.8 Other specified congenital malformations of face and neck	PE
Medial cyst of face and neck	
Medial fistula of face and neck	
Medial sinus of face and neck	
Q18.9 Congenital malformation of face and neck, unspecified	PE
Congenital anomaly NOS of face and neck	

Congenital malformations of the circulatory system (Q20–Q28)

Q20 Congenital malformations of cardiac chambers and connections	
EXCLUDES 1 dextrocardia with situs inversus (Q89.3)	
mirror-image atrial arrangement with situs inversus (Q89.3)	
Q20.0 Common arterial trunk	MCC PE
Persistent truncus arteriosus	
EXCLUDES 1 aortic septal defect (Q21.4)	
Q20.1 Double outlet right ventricle	MCC PE
Taussig-Bing syndrome	
Q20.2 Double outlet left ventricle	MCC PE
Q20.3 Discordant ventriculoarterial connection	MCC PE
Dextrotransposition of aorta	
Transposition of great vessels (complete)	
Q20.4 Double inlet ventricle	MCC PE
Common ventricle	
Cor triloculare biventriculatum	
Single ventricle	
Q20.5 Discordant atrioventricular connection	CC PE
Corrected transposition	
Levotransposition	
Ventricular inversion	
Q20.6 Isomerism of atrial appendages	PE
Isomerism of atrial appendages with asplenia or polysplenia	
Q20.8 Other congenital malformations of cardiac chambers and connections	PE
Cor binoculare	
Q20.9 Congenital malformation of cardiac chambers and connections, unspecified	PE

Q21 Congenital malformations of cardiac septa


EXCLUDES 1 acquired cardiac septal defect (I51.0)

Q21.0 Ventricular septal defect

Roger's disease

CC PE


Ventricular Septal Defect



Q21.1 Atrial septal defect

EXCLUDES 2 ostium primum atrial septal defect (type I) (Q21.20)
AHA: 2022,4Q,39-40

Atrial Septal Defect



Q21.10 Atrial septal defect, unspecified

Q21.11 Secundum atrial septal defect

Fenestrated atrial septum
Patent or persistent ostium secundum defect (type II)

Q21.12 Patent foramen ovale

Persistent foramen ovale

Q21.13 Coronary sinus atrial septal defect

Coronary sinus defect
Unroofed coronary sinus

Q21.14 Superior sinus venosus atrial septal defect

Superior vena cava type atrial septal defect

Q21.15 Inferior sinus venosus atrial septal defect

Inferior vena cava type atrial septal defect

Q21.16 Sinus venosus atrial septal defect, unspecified

Sinus venosus defect, NOS

Q21.19 Other specified atrial septal defect

Common atrium
Other specified atrial septal abnormality

<p>T80.419 Rh incompatibility with hemolytic transfusion reaction, unspecified Rh incompatibility with hemolytic transfusion reaction at unspecified time after transfusion Hemolytic transfusion reaction (HTR) due to Rh incompatibility NOS</p>	<p>T80.6 Other serum reactions Intoxication by serum Protein sickness Serum rash Serum sickness Serum urticaria EXCLUDES 2 serum hepatitis (B16-B19) DEF: Serum sickness: Hypersensitivity to a foreign serum that causes fever, hives, swelling, and lymphadenopathy.</p>
<p>T80.49 Other Rh incompatibility reaction due to transfusion of blood or blood products Delayed serologic transfusion reaction (DSTR) from Rh incompatibility Other reaction to Rh incompatible blood transfusion</p>	<p>T80.61 Other serum reaction due to administration of blood and blood products AHA:2021,1Q,42</p>
<p>T80.A Non-ABO incompatibility reaction due to transfusion of blood or blood products Reaction due to incompatibility of minor antigens (Duffy) (Kell) (Kidd) (Lewis) (M) (N) (P) (S)</p>	<p>T80.62 Other serum reaction due to vaccination AHA:2021,1Q,42</p>
<p>T80.A0 Non-ABO incompatibility reaction due to transfusion of blood or blood products, unspecified Non-ABO antigen incompatibility reaction from transfusion NOS</p>	<p>T80.69 Other serum reaction due to other serum Code also, if applicable, arthropathy in hypersensitivity reactions classified elsewhere (M36.4)</p>
<p>T80.A1 Non-ABO incompatibility with hemolytic transfusion reaction T80.A10 Non-ABO incompatibility with acute hemolytic transfusion reaction Acute hemolytic transfusion reaction (AHTR) due to non-ABO incompatibility Non-ABO incompatibility with hemolytic transfusion reaction less than 24 hours after transfusion</p>	<p>T80.8 Other complications following infusion, transfusion and therapeutic injection T80.81 Extravasation of vesicant agent Infiltration of vesicant agent</p>
<p>T80.A11 Non-ABO incompatibility with delayed hemolytic transfusion reaction Delayed hemolytic transfusion reaction (DHTR) due to non-ABO incompatibility Non-ABO incompatibility with hemolytic transfusion reaction 24 or more hours after transfusion</p>	<p>T80.810 Extravasation of vesicant antineoplastic chemotherapy Infiltration of vesicant antineoplastic chemotherapy</p>
<p>T80.A19 Non-ABO incompatibility with hemolytic transfusion reaction, unspecified Hemolytic transfusion reaction (HTR) due to non-ABO incompatibility NOS Non-ABO incompatibility with hemolytic transfusion reaction at unspecified time after transfusion</p>	<p>T80.818 Extravasation of other vesicant agent Infiltration of other vesicant agent</p>
<p>T80.A9 Other non-ABO incompatibility reaction due to transfusion of blood or blood products Delayed serologic transfusion reaction (DSTR) from non-ABO incompatibility Other reaction to non-ABO incompatible blood transfusion</p>	<p>T80.82 Complication of immune effector cellular therapy Complication of chimeric antigen receptor (CAR-T) cell therapy Complication of IEC therapy Use additional code to identify the specific complication, such as: cytokine release syndrome (D89.83-) immune effector cell-associated neurotoxicity syndrome (G92.0-)</p>
<p>T80.5 Anaphylactic reaction due to serum Allergic shock due to serum Anaphylactic shock due to serum Anaphylactoid reaction due to serum Anaphylaxis due to serum EXCLUDES 1 ABO incompatibility reaction due to transfusion of blood or blood products (T80.3-) allergic reaction or shock NOS (T78.2) anaphylactic reaction or shock NOS (T78.2) anaphylactic reaction or shock due to adverse effect of correct medicinal substance properly administered (T88.6) other serum reaction (T80.6-) DEF: Life-threatening hypersensitivity to a foreign serum causing respiratory distress, vascular collapse, and shock.</p>	<p>EXCLUDES 2 ▶adverse effect of immune checkpoint inhibitors and immunostimulant drugs (T45.AX5)◀ complication of bone marrow transplant (T86.0) complication of stem cell transplant (T86.5) AHA:2021,4Q,31</p>
<p>T80.51 Anaphylactic reaction due to administration of blood and blood products T80.52 Anaphylactic reaction due to vaccination AHA:2021,1Q,43 T80.59 Anaphylactic reaction due to other serum</p>	<p>T80.89 Other complications following infusion, transfusion and therapeutic injection Delayed serologic transfusion reaction (DSTR), unspecified incompatibility Use additional code to identify graft-versus-host reaction, if applicable, (D89.81-) AHA:2020,4Q,14</p>
<p>T80.9 Unspecified complication following infusion, transfusion and therapeutic injection T80.90 Unspecified complication following infusion and therapeutic injection T80.91 Hemolytic transfusion reaction, unspecified incompatibility</p>	<p>EXCLUDES 1 ABO incompatibility with hemolytic transfusion reaction (T80.31-) non-ABO incompatibility with hemolytic transfusion reaction (T80.A1-) Rh incompatibility with hemolytic transfusion reaction (T80.41-)</p>
<p>T80.910 Acute hemolytic transfusion reaction, unspecified incompatibility T80.911 Delayed hemolytic transfusion reaction, unspecified incompatibility T80.919 Hemolytic transfusion reaction, unspecified incompatibility, unspecified as acute or delayed</p>	<p>Hemolytic transfusion reaction NOS</p>
<p>T80.92 Unspecified transfusion reaction</p>	<p>Transfusion reaction NOS</p>

Appendix G: Hospital Acquired Conditions

Hospital-acquired conditions (HACs) are conditions considered reasonably preventable through the application of evidence-based guidelines. These conditions, in and of themselves, are either a complication or comorbidity (CC) or major complication or comorbidity (MCC) that as a secondary diagnosis will move the MS-DRG assignment from a lower-paying MS-DRG to a higher-paying MS-DRG. However, if these conditions are not present on admission (meaning they developed during the hospital stay), the CC or MCC designation is nullified and the case will not group to the higher-paying MS-DRG based solely upon the reporting of the HAC code.


HACs are grouped into 14 categories. ICD-10-CM codes in the tabular section of this book that are grouped to one of these HAC categories are identified by an icon specific to that category. As many of these HACs are conditional, this resource provides any additional stipulations that may be required before the code can be considered an HAC. For example, code I26.02 has an  indicating it falls in the HAC 10 category for Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) with Total Knee or Hip Replacement. However, I26.02 is not, by itself, a HAC. There must also be a specific ICD-10-PCS code, such as 0SR9019 Replacement of Right Hip Joint with Metal Synthetic Substitute, Cemented, Open Approach, applied in order for I26.02 to act as a HAC.

Note: The resource used to compile this list is based on the proposed, version 42, MS-DRG Grouper software and Definitions Manual files published with the fiscal 2025 IPPS proposed rule. The final, version 42, MS-DRG Grouper files and MS-DRG Definitions Manual files can be found at the following: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/IPPS-Regulations-and-Notices.html>.

HAC 01: Foreign Object Retained After Surgery	HAC 03: Blood Incompatibility	HAC 05: Falls and Trauma	\$02.40BA	\$02.81XA	\$06.322A	\$06.384A	\$06.899A	\$12.150B
Secondary diagnosis not POA:	Secondary diagnosis not POA:	Secondary diagnosis not POA:	\$02.40BB	\$02.81XB	\$06.323A	\$06.385A	\$06.89AA	\$12.151A
T80.30XA	M99.10	\$02.40CA	\$02.82XA	\$06.324A	\$06.386A	\$06.8A0A	\$12.151B	
T80.310A	M99.11	\$02.40CB	\$02.82XB	\$06.325A	\$06.387A	\$06.8A1A	\$12.190A	
T81.500A	T80.311A	\$02.40DA	\$02.831A	\$06.326A	\$06.388A	\$06.8A2A	\$12.190B	
T81.501A	T80.319A	\$02.40DB	\$02.831B	\$06.327A	\$06.389A	\$06.8A3A	\$12.191A	
T81.502A	T80.39XA	\$02.40EA	\$02.832A	\$06.328A	\$06.38AA	\$06.8A4A	\$12.191B	
T81.503A	T80.311A	M99.18	\$02.40EB	\$02.832B	\$06.329A	\$06.4X0A	\$06.8A5A	\$12.200A
T81.504A	HAC 04: Stage III and IV Pressure Ulcers	\$02.40FA	\$02.839A	\$06.32AA	\$06.4X1A	\$06.8A6A	\$12.200B	
T81.505A	T80.319A	\$02.40FB	\$02.839B	\$06.330A	\$06.4X2A	\$06.8A7A	\$12.201A	
T81.506A	T80.39XA	\$02.411A	\$02.841A	\$06.331A	\$06.4X3A	\$06.8A8A	\$12.201B	
T81.507A	T80.310A	\$02.411B	\$02.841B	\$06.332A	\$06.4X4A	\$06.8A9A	\$12.230A	
T81.508A	T80.319B	\$02.412A	\$02.842A	\$06.333A	\$06.4X5A	\$06.8AAA	\$12.230B	
T81.509A	T80.39XA	\$02.412B	\$02.842B	\$06.334A	\$06.4X6A	\$06.9X1A	\$12.231A	
T81.510A	L89.003	\$02.413A	\$02.849A	\$06.335A	\$06.4X7A	\$06.9X2A	\$12.231B	
T81.511A	L89.004	\$02.400B	\$02.91XA	\$06.33AA	\$06.5X1A	\$06.9X7A	\$12.251A	
T81.512A	L89.013	\$02.411B	\$02.901A	\$02.92XA	\$06.340A	\$06.5X2A	\$06.9X8A	\$12.251B
T81.513A	L89.014	\$02.411A	\$02.901B	\$02.92XB	\$06.341A	\$06.5X3A	\$06.9X9A	\$12.290A
T81.514A	L89.023	\$02.411B	\$02.902A	\$06.0X1A	\$06.342A	\$06.5X4A	\$06.9X4A	\$12.24XB
T81.515A	L89.024	\$02.411A	\$02.902B	\$06.285X	\$06.338A	\$06.4XAA	\$06.9X5A	\$12.250A
T81.516A	L89.024	\$02.411B	\$02.900A	\$06.339A	\$06.5X0A	\$06.9X6A	\$12.250B	
T81.517A	L89.024	\$02.411A	\$02.900B	\$02.91XB	\$06.33AA	\$06.5X1A	\$06.9X7A	\$12.251A
T81.518A	L89.024	\$02.411B	\$02.901A	\$02.92XA	\$06.340A	\$06.5X2A	\$06.9X8A	\$12.251B
T81.519A	L89.114	\$02.411A	\$02.901B	\$02.92XB	\$06.341A	\$06.5X3A	\$06.9X9A	\$12.290A
T81.520A	L89.123	\$02.411B	\$02.902A	\$06.0X1A	\$06.342A	\$06.5X4A	\$06.9XAA	\$12.290B
T81.521A	L89.124	\$02.411A	\$02.902B	\$06.0X9A	\$06.343A	\$06.5X5A	\$07.0XXXA	\$12.291A
T81.522A	L89.133	\$02.411B	\$02.909A	\$06.0XAA	\$06.344A	\$06.5X6A	\$07.1XXA	\$12.291B
T81.523A	L89.134	\$02.411A	\$02.909B	\$06.1X1A	\$06.345A	\$06.5X7A	\$07.8XXXA	\$12.300A
T81.524A	L89.143	\$02.411B	\$02.610A	\$06.1X2A	\$06.346A	\$06.5X8A	\$07.9XXXA	\$12.300B
T81.525A	L89.144	\$02.411CA	\$02.620A	\$06.1X3A	\$06.347A	\$06.5X9A	\$12.000A	\$12.301A
T81.526A	L89.153	\$02.411CB	\$02.621A	\$06.1X4A	\$06.348A	\$06.5XAA	\$12.000B	\$12.301B
T81.527A	L89.154	\$02.411DA	\$02.621B	\$06.1X5A	\$06.349A	\$06.6X0A	\$12.001A	\$12.330A
T81.528A	L89.203	\$02.411DB	\$02.621B	\$06.1X6A	\$06.34AA	\$06.6X1A	\$12.001B	\$12.330B
T81.529A	L89.204	\$02.411EA	\$02.622A	\$06.1X7A	\$06.350A	\$06.6X2A	\$12.01XA	\$12.331A
T81.530A	L89.213	\$02.411EB	\$02.622B	\$06.2X3A	\$06.351A	\$06.6X3A	\$12.01XB	\$12.331B
T81.531A	L89.214	\$02.411FA	\$02.630A	\$06.2X4A	\$06.352A	\$06.6X4A	\$12.02XA	\$12.34XA
T81.532A	L89.223	\$02.411FB	\$02.630B	\$06.2X5A	\$06.353A	\$06.6X5A	\$12.02XB	\$12.34XB
T81.533A	L89.224	\$02.411GA	\$02.631A	\$06.2X6A	\$06.354A	\$06.6X6A	\$12.030A	\$12.350A
T81.534A	L89.303	\$02.411GB	\$02.631B	\$06.2X7A	\$06.355A	\$06.6X7A	\$12.030B	\$12.350B
T81.535A	L89.304	\$02.411HA	\$02.632A	\$06.2X8A	\$06.356A	\$06.6X8A	\$12.031A	\$12.351A
T81.536A	L89.313	\$02.411HB	\$02.632B	\$06.2X9A	\$06.361A	\$06.6X9A	\$12.031B	\$12.351B
T81.537A	L89.314	\$02.412A	\$02.640A	\$06.2X5A	\$06.358A	\$06.6XAA	\$12.040A	\$12.390A
T81.538A	L89.323	\$02.412B	\$02.640B	\$06.301A	\$06.359A	\$06.811A	\$12.040B	\$12.390B
T81.539A	L89.324	\$02.412A	\$02.641A	\$06.302A	\$06.364A	\$06.812A	\$12.041A	\$12.391A
T81.540A	L89.43	\$02.412B	\$02.641B	\$06.303A	\$06.365A	\$06.818A	\$12.041B	\$12.391B
T81.541A	L89.44	\$02.412A	\$02.642A	\$06.304A	\$06.366A	\$06.819A	\$12.090A	\$12.400A
T81.542A	L89.503	\$02.412B	\$02.642B	\$06.305A	\$06.367A	\$06.81AA	\$12.101A	\$12.431A
T81.543A	L89.504	\$02.419XA	\$02.650A	\$06.306A	\$06.368A	\$06.821A	\$12.101B	\$12.431B
T81.544A	L89.513	\$02.419XB	\$02.650B	\$06.307A	\$06.369A	\$06.822A	\$12.110A	\$12.44XA
T81.545A	L89.514	\$02.42XXB	\$02.651A	\$06.308A	\$06.36AA	\$06.823A	\$12.110B	\$12.44XB
T81.546A	L89.523	\$02.30XA	\$02.652A	\$06.309A	\$06.370A	\$06.824A	\$12.111A	\$12.450A
T81.547A	L89.524	\$02.30XB	\$02.652B	\$06.310A	\$06.371A	\$06.825A	\$12.111B	\$12.450B
T81.548A	L89.603	\$02.31XA	\$02.66XA	\$06.311A	\$06.372A	\$06.826A	\$12.112A	\$12.451A
T81.549A	L89.604	\$02.31XB	\$02.66XB	\$06.312A	\$06.373A	\$06.827A	\$12.112B	\$12.451B
T81.600A	L89.613	\$02.32XA	\$02.670A	\$06.313A	\$06.375A	\$06.828A	\$12.120A	\$12.490A
T81.610A	L89.614	\$02.32XB	\$02.670B	\$06.314A	\$06.376A	\$06.829A	\$12.120B	\$12.490B
T81.619A	L89.623	\$02.400A	\$02.671A	\$06.315A	\$06.377A	\$06.891A	\$12.121A	\$12.491A
HAC 02: Air Embolism	L89.624	\$02.400B	\$02.671B	\$06.316A	\$06.378A	\$06.892A	\$12.130A	\$12.500A
Secondary diagnosis not POA:	L89.813	\$02.401A	\$02.672A	\$06.317A	\$06.379A	\$06.893A	\$12.130B	\$12.500B
L89.814	\$02.401B	\$02.672B	\$06.318A	\$06.37AA	\$06.894A	\$12.131A	\$12.501A	
L89.893	\$02.402A	\$02.69XA	\$06.319A	\$06.380A	\$06.895A	\$12.131B	\$12.501B	
L89.894	\$02.402B	\$02.69XB	\$06.31AA	\$06.381A	\$06.896A	\$12.14XA	\$12.530A	
L89.93	\$02.40AA	\$02.80XA	\$06.320A	\$06.382A	\$06.897A	\$12.14XB	\$12.530B	
T80.0XXA	L89.94	\$02.40AB	\$02.80XB	\$06.321A	\$06.383A	\$06.898A	\$12.150A	\$12.531A

Chapter 9. Diseases of the Circulatory System (I00–I99)

Anatomy of the Heart



Heart Cross Section

